Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada

Author： Marshall Deborah A.   Douglas Patrick R.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.26, Iss.6, 2008-01, pp. : 477-495

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Economic Impact of Introducing Serotonin-Noradrenaline Reuptake Inhibitors into the Brazilian National Drug Formulary: Cost-Effectiveness and Budget-Impact Analyses

By Machado Márcio   Iskedjian Michael  

PharmacoEconomics, Vol. 25, Iss. 11, 2007-01 ,pp. : 979-990

Adis International

Access to resources Recommend Favorite

Budget-Impact Analyses: A Critical Review of Published Studies

By Orlewska Ewa  

PharmacoEconomics, Vol. 27, Iss. 10, 2009-10 ,pp. : 807-827

Adis International

Access to resources Recommend Favorite

The Japan PDMA will require pharmaceutical companies to include risk management plans in all applications, for new drug or biosimilar products

By  

Reactions Weekly, Vol. 1, Iss. 1431, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Internet drug trade could hurt Canada's public health

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 443, 2003-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Methodological Hurdles in Conducting Pharmacoeconomic Analyses

By Douglasrizzo J.  

PharmacoEconomics, Vol. 15, Iss. 4, 1999-04 ,pp. : 339-355

Adis International

Access to resources Recommend Favorite